More Videos:

How the U.S. Government Makes Money on Cannabis

Tickers in this article: ABBV GWPH

NEW YORK ( TheStreet) -- The government makes money off of cannabis; the same cannabis it declares illegal. The same cannabis it throws people into prison for selling.

The National Institute of Health received a patent on cannabinoids in October 2003 . Aidan Hampson, the scientist who made the discovery while working at the Institute of Mental Health said, "I discovered the cannabinoid receptor in the brain that THC [the active chemical in marijuana] binds to. THC mimics something that occurs naturally in the brain and I asked myself, what's the natural key to this lock?" Hampson said if a scientist believes something could be important, then you patent it immediately.

"Any discovery you make, you hope it has a therapeutic benefit," said Hampson. In order to eventually get that discovery to patients, a drug needs to go through clinical trials. No drug company will pursue drug development unless they know who owns the intellectual property. "It would cost approximately $30 million to do a test." said Hampson. "No company will give you a second glance unless you own the intellectual property." Meaning, they won't want to spend the money unless they can recoup the cost of the test and they need the patent or a license on the drug in order to do so.

In June of 2013, the NIH granted the exclusive license to phyto-medical company KannaLife Sciences . Dean Petkanus CEO of KannaLife said it was very difficult to get the exclusive license to the patent. The company has the license for only one disease, Hepatic Encephalopathy, that is associated with liver disorders. It occurs in people with cirrhosis from alcoholism or hepatitis C and B as a couple of examples.

Petkanus believes that KannaLife's product could be a $1 billion-to-$2 billion drug with a potential patient population of 1.5 million. Petkanus would not say how much they would have to pay to NIH as a result of the agreement saying, "We can't disclose the terms." However, KannaLife has made several payments already to NIH for royalty fees, continuous use fees and prosecution fees. "We have made payments to the NIH. Absolutely," said Petkanus.

The patent expires in February 2021, but KannaLife believes it will have a product to market before that time. KannaLife also believes the product will have FDA approval which means the FDA would have to reschedule the classification of cannabis.

Marijuana is currently defined as a schedule 1 controlled substance meaning it is a dangerous drug and has no medicinal benefits (even though the NIH filed for the patent stating the cannabinoids could treat diseases like Alzheimer's, Parkinson's, HIV and could limit damage in strokes and trauma.) Congress has many pieces of legislation addressing marijuana, but isn't expected to change the status anytime soon.